What Is PCOS? Canadian Guide (2026)
PCOS (polycystic ovary syndrome) affects an estimated 8–13% of Canadian women of reproductive age, making it one of the most common endocrine conditions in the country — yet up to 70% of cases go undiagnosed globally, per the 2023 International Evidence-Based Guideline for the Assessment and Management of PCOS. Diagnosis follows the Rotterdam criteria: two of three features — androgen excess, ovulatory dysfunction, or polycystic ovarian morphology on ultrasound — after excluding other causes such as thyroid disease. PCOS is driven by insulin resistance (present in an estimated 65–95% of patients) and elevated androgens, which together produce irregular periods, unwanted hair growth, acne, scalp thinning, and central weight gain. Left unmanaged, PCOS raises long-term risk for type 2 diabetes, cardiovascular disease, and endometrial hyperplasia. In May 2026, the condition was officially renamed PMOS (polyendocrine metabolic ovarian syndrome) by global consensus in The Lancet — diagnostic criteria and treatment are unchanged. For treatment options, see the Canadian PCOS treatment guide and PCOS belly fat.
Update — May 2026: PCOS has been officially renamed polyendocrine metabolic ovarian syndrome (PMOS) by global consensus published in The Lancet and endorsed by the Endocrine Society. The condition, diagnostic criteria, and treatment framework are unchanged — only the name. See our explainer on the PCOS-to-PMOS rename and what it means for Canadians. The article below continues to use "PCOS" because that remains the term most patients are searching for and the term most Canadian charts still use during the transition period.
What PCOS actually is
Polycystic ovary syndrome — PCOS — is a chronic hormonal and metabolic condition that affects roughly 8–13% of women of reproductive age in Canada, according to the Society of Obstetricians and Gynaecologists of Canada (SOGC). If you have been told you might have PCOS, or have been recently diagnosed, the core things to understand are: what causes it, how it is diagnosed, and what the long-term risks are — all covered below. International data suggests that up to 70% of cases go undiagnosed worldwide, a figure the 2023 International Evidence-Based Guideline for the Assessment and Management of PCOS flags as a major gap in care.
PCOS is not a single disease with a single test. It is a syndrome — a recognizable pattern that emerges from three overlapping features:
- Excess androgens. The ovaries (and sometimes the adrenal glands) produce higher-than-typical levels of testosterone and related hormones.
- Ovulatory dysfunction. Ovulation becomes irregular, infrequent, or stops altogether.
- Polycystic ovarian morphology. The ovaries develop many small fluid-filled follicles visible on ultrasound. These are not true cysts in the harmful sense — the name is historical and somewhat misleading.
A diagnosis requires at least two of these three features, with other causes (thyroid disease, hyperprolactinemia, congenital adrenal hyperplasia, Cushing syndrome) ruled out first. That framework is known as the Rotterdam criteria.
Take the free 3-minute quiz
The Rotterdam criteria, briefly
The Rotterdam ESHRE/ASRM consensus, originally published in 2003 and reaffirmed by the 2023 international guideline, is the diagnostic standard Canadian clinicians use. The Endocrine Society's PCOS clinical practice guideline also anchors to it.
Two of the following three, after excluding other causes:
- Clinical or biochemical evidence of hyperandrogenism — this can be physical signs (hirsutism, severe acne, scalp hair thinning) or elevated androgens on bloodwork (total or free testosterone, DHEA-S, or a calculated free androgen index).
- Oligo- or anovulation — cycles longer than 35 days, fewer than eight cycles per year, or absent menstruation in the absence of pregnancy or menopause.
- Polycystic ovarian morphology on ultrasound — historically defined as 12 or more follicles measuring 2–9 mm in either ovary, or an increased ovarian volume above 10 mL. Newer ultrasound technology has revised the follicle threshold upward, and the 2023 guideline now allows anti-Müllerian hormone (AMH) blood testing as an alternative in adult women when ultrasound is not feasible.
Two features — not three — are enough. That is why PCOS presents so heterogeneously: a woman with hirsutism and irregular periods can have a clear PCOS diagnosis with completely normal-looking ovaries on ultrasound, while another with clinical androgen excess and polycystic morphology can be diagnosed even if her cycles are regular.
How common PCOS is in Canada
The SOGC cites a Canadian prevalence in the 8–13% range among women of reproductive age, consistent with the international figure published in the 2023 guideline. The variation in that range reflects the diagnostic criteria used — broader Rotterdam criteria identify more women than the older, narrower National Institutes of Health (NIH) 1990 criteria did.
That prevalence makes PCOS substantially more common in Canadian women than type 2 diabetes in the same age range. It is also more common than asthma, more common than thyroid disease in women under 50, and roughly as common as iron-deficiency anemia. Despite this, PCOS receives a small fraction of the public-health attention these conditions get, and many Canadian women wait years between symptom onset and a formal diagnosis.
The most common starting point for a Canadian woman with PCOS is her family physician. The most common reason for delayed diagnosis is that the symptoms — irregular periods, weight gain, acne, mood changes — get attributed individually to stress, lifestyle, or "just hormones," instead of recognized as the connected pattern they are.
The full PCOS symptom map
PCOS is a syndrome, which means the symptom list is long and no two women present identically. Below is the full symptom map grouped by the underlying mechanism — useful both for self-recognition and for the conversation with your physician.
Hyperandrogenism — the androgen-excess symptoms
These are driven by elevated testosterone, DHEA, or both:
- Hirsutism — coarse, dark, terminal hair growth in a male-pattern distribution (chin, upper lip, chest, abdomen, lower back). Affects roughly 70% of women with PCOS in some populations.
- Acne, especially adult acne — typically along the jawline, chin, and upper neck; often persists or first appears in the twenties or later.
- Scalp hair thinning — diffuse thinning at the crown and along the part line, sometimes called female-pattern hair loss or androgenetic alopecia.
- Skin changes — oily skin, occasionally acanthosis nigricans (darkened, velvety patches in skin folds — usually a sign of insulin resistance rather than androgen excess directly).
Ovulatory dysfunction — the cycle symptoms
These are driven by irregular or absent ovulation:
- Long or irregular menstrual cycles — cycles longer than 35 days are the most common pattern.
- Infrequent periods — fewer than 8–9 periods in a year (oligomenorrhea).
- Absent periods — amenorrhea, especially after years of irregularity.
- Difficulty getting pregnant — PCOS is the most common cause of anovulatory infertility worldwide.
- Heavier or unpredictable bleeding when periods do occur.
Polycystic ovarian morphology — the imaging finding
Not really a symptom you feel; rather, what shows up on transvaginal or abdominal ultrasound. The ovaries appear enlarged with many small follicles arranged around the periphery — sometimes described as a "string of pearls" appearance.
Metabolic features — often the most consequential long-term
These are tied to insulin resistance, which affects an estimated 65–95% of women with PCOS, even at normal body weight:
- Weight gain, especially central or abdominal — disproportionate accumulation around the midsection that resists ordinary diet-and-exercise approaches. See our article on PCOS belly fat for the mechanism and what the evidence shows actually works.
- Difficulty losing weight — even with sustained calorie restriction.
- Increased hunger or strong cravings — particularly for refined carbohydrates.
- Energy crashes after carbohydrate-heavy meals.
- Acanthosis nigricans — the velvety dark patches mentioned above.
- Skin tags, often around the neck and armpits.
- Elevated fasting insulin, fasting glucose, or HbA1c on bloodwork.
- Dyslipidemia — elevated triglycerides, lower HDL.
Mood, sleep, and quality-of-life features
Increasingly recognized as part of the PCOS picture, not as separate issues:
- Higher rates of anxiety and depression than age-matched controls.
- Disordered sleep, including a higher prevalence of obstructive sleep apnea.
- Fatigue — both from the metabolic and hormonal load and from sleep disruption.
- Body-image distress related to the visible symptoms (acne, hirsutism, weight changes).
A woman with PCOS may have all of these, several of them, or only a few. The pattern matters more than any single symptom.
See if Cloudcure is right for you
Why female-presenting bodies specifically
PCOS occurs in female-bodied people because it is, at its core, a disorder of the ovaries and of the female-typical endocrine axis that regulates them. Two specific features explain why the syndrome takes the shape it does in women:
1. The ovaries are the dominant androgen producer. In a woman with PCOS, the ovarian theca cells overproduce androgens, which is the proximate driver of hirsutism, acne, and hair-pattern changes. Adrenal androgens contribute in a subset of cases, but the ovary is the primary site.
2. The hypothalamic-pituitary-ovarian (HPO) axis is structured around cyclical ovulation. PCOS disrupts that cycle — typically through an elevated LH:FSH ratio and irregular GnRH pulsatility — which is why oligomenorrhea and anovulatory infertility are core features.
Some patients with PCOS are non-binary or transgender, and the diagnosis still applies based on the underlying anatomy and endocrine pattern. The Canadian medical literature increasingly uses female-bodied or people with ovaries in PCOS guidance to reflect that the syndrome is defined by physiology rather than gender identity.
PCOS vs PCOD — what is the difference, actually?
A short answer, because this comes up constantly in Canadian patient questions:
- PCOD stands for polycystic ovarian disease. It is an older, somewhat outdated term that emphasizes the ovarian appearance — the "many small follicles" finding — over the broader syndrome.
- PCOS stands for polycystic ovary syndrome. It is the current clinical term and captures the full hormonal-and-metabolic picture, not just the ovaries.
In casual use, especially in South Asian, Southeast Asian, and online communities, PCOD is still common and often used to describe milder or symptom-light cases. In Canadian clinical practice and in international guidelines, PCOS is the operative term. They are not two different diseases — PCOD, when it means anything specific, is a subset of how PCOS can present.
If your physician has used one term and you have read about the other, you are looking at the same condition.
PCOS in French — SOPK and ovaire polykystique
For francophone Canadians, especially in Quebec, the terminology is:
- SOPK — syndrome des ovaires polykystiques (the direct French equivalent of PCOS, used in clinical settings).
- Ovaire polykystique — the singular ovarian-morphology term; appears frequently in patient-facing material and search.
The condition is identical. The Société des obstétriciens et gynécologues du Canada provides francophone resources, and the diagnostic criteria, treatment framework, and Canadian prevalence figures all apply equally. Where this matters practically: if you are searching for information in French or speaking with a francophone physician, ask about SOPK rather than PCOS and you will get the right material.
What happens if PCOS is left untreated
This is the part most patients deserve to hear early, because the long-term picture is what makes early action worthwhile.
Unmanaged PCOS is associated with elevated risk of:
- Type 2 diabetes. The lifetime risk in women with PCOS is several-fold higher than in age-matched women without PCOS. The Diabetes Canada Clinical Practice Guidelines recommend periodic screening for women with PCOS.
- Gestational diabetes during pregnancy.
- Dyslipidemia and hypertension — elevated triglycerides, lower HDL, higher blood pressure, contributing to long-term cardiovascular risk.
- Non-alcoholic fatty liver disease (NAFLD/MASLD). PCOS roughly doubles the risk, mediated largely by insulin resistance.
- Endometrial hyperplasia and, in some cases, endometrial cancer, driven by chronic unopposed estrogen exposure when ovulation is absent. This is one of the strongest reasons to manage cycle regulation in PCOS even when fertility is not currently a goal.
- Infertility and pregnancy complications. PCOS is the leading cause of anovulatory infertility; pregnancies in women with PCOS carry higher rates of gestational diabetes, hypertensive disorders, and preterm birth.
- Mood disorders. Anxiety and depression are more prevalent and warrant active screening per the 2023 international guideline.
- Cardiovascular disease over the long term, driven by the metabolic features above.
The 2023 international guideline is explicit that these risks are modifiable in most women through early identification and structured management. Lifestyle-first care, then layered clinical support where appropriate, is the framework — the same three-pillar approach the 2020 Canadian Adult Obesity Clinical Practice Guideline uses for related metabolic conditions.
How PCOS is managed — the short version
A full treatment guide is its own article, but the framework Canadian clinicians use, anchored to the 2023 international guideline, runs roughly:
- Lifestyle as the foundation. Sustained 5–10% weight reduction (in women with overweight or obesity) is the single highest-evidence intervention — it improves ovulation, insulin sensitivity, and androgen levels. Dietary patterns that lower glycemic load and adequate protein are emphasized. Resistance training matters more in PCOS than for most populations.
- Cycle regulation and androgen management. Combined hormonal contraception is a common first-line option for cycle regulation and for managing hirsutism and acne when fertility is not currently a goal.
- Insulin sensitization. An insulin-sensitizing medication is well-established and recommended as an adjunct in PCOS, especially when metabolic features dominate. It is a recognized first-line option in Canadian metabolic care and is widely covered by provincial plans.
- Targeted fertility care when pregnancy is the goal — typically managed by an OB-GYN or reproductive endocrinologist.
- Mental-health screening and support, given the elevated rates of anxiety and depression in this population.
- Long-term cardiometabolic monitoring — periodic HbA1c, lipid panel, blood pressure, and weight tracking through your family physician or specialist clinic.
For the specific case of PCOS-driven abdominal fat — one of the most common patient concerns — see our article on PCOS belly fat. For an overview of how clinician-led weight management actually works in Canada, see prescription weight management in Canada. For how to pay for structured care, see our guide to using a Health Spending Account for weight loss in Canada.
Start your eligibility check
How Cloudcure approaches PCOS
PCOS sits at the intersection of three clinical areas — endocrinology, metabolic medicine, and women's health — and Canadian primary care is rarely structured to give all three the time they deserve. Most Canadian women with PCOS receive a diagnosis, a brief discussion, and then are sent home to manage a chronic, multi-system condition on their own.
Cloudcure's PCOS care program is built around the metabolic side of PCOS specifically:
- A baseline workup that includes HbA1c, fasting insulin, lipid panel, ALT/AST, and a free-androgen-index calculation where appropriate — so the picture is measured, not assumed.
- A 12-month structured arc anchored to the 5–10% sustained weight-reduction target where weight is part of the picture, with monthly clinician follow-up and lab reviews at months 3, 6, and 12.
- Behavioural and nutritional coaching built around the dietary-pattern principles the 2023 guideline supports.
- Coordination with your family physician, OB-GYN, or endocrinologist — Cloudcure handles the metabolic arc that most primary-care practices don't have the bandwidth to run, and refers back where clinical complexity calls for it.
Membership is $69/month and is HSA- and HCSA-eligible across major Canadian benefits providers, consistent with the coverage framework described by Obesity Canada.
The bottom line on PCOS
Four things worth holding onto:
- PCOS is common, chronic, and manageable. It affects roughly 8–13% of Canadian women of reproductive age. It is not a personal failing and not a temporary problem.
- It is a syndrome, not a single disease. The Rotterdam criteria — two of three features after other causes are excluded — is the diagnostic standard your physician will use.
- The long-term risks are real and modifiable. Type 2 diabetes, cardiovascular disease, endometrial issues, fertility challenges — all are elevated in unmanaged PCOS and all are reduced by early, structured management.
- You are not stuck with generic advice. The 2023 international guideline, the SOGC, and the Endocrine Society all describe a clear evidence-based framework. Working with a clinician who runs that framework — whether your family physician, your OB-GYN, an endocrinologist, or a structured program like Cloudcure — is what closes the gap.
If you suspect you have PCOS and haven't yet had a workup, start with your family physician. If you have a diagnosis and want structured metabolic care alongside your existing providers, take Cloudcure's three-minute eligibility check — for many people the honest answer is that primary care has them covered, and we will say so.
For the full set of Canadian PCOS resources in one place — diagnosis, treatment, belly fat, and the metabolic connection — start at our PCOS resource hub. And because PCOS does not end at menopause, our guide to perimenopause and weight gain in Canada explains how the two life stages overlap.